Lipid-lowering therapy does not affect the postprandial drop in high density lipoprotein-cholesterol (HDL-c) plasma levels in obese men with metabolic syndrome: A randomized double blind crossover trial

Clinical Endocrinology

Volumn 69, Issue 6, 2008, Pages 870-877

  Hajer, Gideon R ^a   Dallinga Thie, Geesje M ^b   Van Vark Van Der Zee, Leonie C ^c   Olijhoek, Jobien K ^a   Visseren, Frank L J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CHOLESTEROL ESTER TRANSFER PROTEIN; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY FAT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; MALE; METABOLIC SYNDROME X; MONOTHERAPY; OBESITY; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; AZETIDINES; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CROSS-OVER STUDIES; DIETARY FATS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FASTING; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; POSTPRANDIAL PERIOD; SIMVASTATIN;

EID: 55949124183     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03250.x     Document Type: Article

References (29)

1. Eckel, R.H., Grundy, S.M. Zimmet, P.Z. (2005) The metabolic syndrome. Lancet, 16, 1415 1428.
2. Liao, Y., Kwon, S., Shaughnessy, S., Wallace, P., Hutto, A., Jenkins, A.J., Klein, R.L. Garvey, W.T. (2004) Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care, 27, 978 983.
3. Van Gaal, L.F., Mertens, I.L. De Block, C.E. (2006) Mechanisms linking obesity with cardiovascular disease. Nature, 444, 875 880.
4. Lind, L., Vessby, B. Sundstrom, J. (2006) The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men. Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 406 410.
5. Pascot, A., Lemieux, I., Prud'homme, D., Tremblay, A., Nadeau, A., Couillard, C., Bergeron, J., Lamarche, B. Després, J.-P 2006) Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity. Journal of Lipid Research, 42, 2007 2014.
6. Assmann, G., Schulte, H., von Eckhardstein, A. Huang, Y. (1996) High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis, 124, S11 S20.
7. Brewer, H.B. Jr., Remaley, A.T., Neufeld, E.B., Basso, F. Joyce, C. (2004) Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 1755 1760.
8. Jiang, X.C., Moulin, P., Quinet, E., Goldberg, I.J., Yacoub, L.K., Agellon, L.B., Compton, D., Schnitzer-Polokoff, R. Tall, A.R. (1991) Mammalian adipose tissue and muscle are major sources of lipid transfer protein mRNA. Journal of Biological Chemistry, 266, 4631 4639.
9. Dullaart, R.P., Dallinga-Thie, G.M., Wolffenbuttel, B.H. Van Tol, A. (2007) CETP inhibition in cardiovascular risk management: a critical appraisal. European Journal of Clinical Investigation, 37, 90 98.
10. Eckel, R.H., Yost, T.J. Jensen, D.R. (1995) Alterations in lipoprotein lipase in insulin resistance. International Journal of Obesity and Related Metabolic Disorders, 19, S16 S21.
11. Kay, R.M., Rao, S., Arnott, C., Miller, N.E. Lewis, B. (1980) Acute effects of the pattern of fat ingestion on plasma high density lipoprotein components in man. Atherosclerosis, 36, 567 573.
12. Groener, J.E., Scheek, L.M., van Ramshorst, E., Krauss, X.H. Van Tol, A. (1998) Delayed increase in high density lipoprotein-phospholipids after ingestion of a fat load in normolipidemic patients with coronary artery disease. Atherosclerosis, 137, 311 319.
13. Lottenberg, S.A., Lottenberg, A.M., Nunes, V.S., McPherson, R. Quintao, E.C. (1996) Plasma cholesteryl ester transfer protein concentration, high-density lipoprotein cholesterol esterification and transfer rates to lighter density lipoproteins in the fasting state and after a test meal are similar in type II diabetics and normal controls. Atherosclerosis, 127, 81 90.
14. Mero, N., Van Tol, A., Scheek, L.M., Van Gent, T., Labeur, C., Rosseneu, M. Taskinen, M.-R. (1998) Decreased postprandial high density lipoprotein cholesterol and apolipoproteins A-I and E in normolipidemic smoking men: relations with lipid transfer proteins and LCAT activities. Journal of Lipid Research, 39, 1493 1502.
15. Feldman, T., Davidson, M., Shah, A., Maccubbin, D., Meehan, A., Zakson, M., Tribble, D., Veltri, E. Mitchel, Y. (2006) Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post hoc analysis of subpopulations from three pooled clinical trials. Clinical Therapeutics, 28, 849 859.
16. Guerin, M., Egger, P., Le Goff, W., Soudant, C., Dupuis, R. Chapman, M.J. (2002) Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIb hyperlipidemia. Journal of Clinical Endocrinology and Metabolism, 87, 4991 5000.
17. Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III 2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Journal of the American Medical Association, 285, 2486 2497.
18. Furuhashi, M., Ura, N., Takizawa, H., Yoshida, D., Moniwa, N., Murakami, H., Higashiura, K. Shimamoto, K. (2004) Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. Journal of Hypertension, 22, 1977 1982.
19. Riemens, S., Van Tol, A., Sluiter, W. Dullaart, R. (1998) Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis, 140, 71 79.
20. Mezdour, H., Kora, I., Parra, H.J., Tartar, A., Marcel, Y.L. Fruchart, J.C. (1994) Two-site enzyme immunoassay of cholesteryl ester transfer protein with monoclonal and oligoclonal antibodies. Clinical Chemistry, 40, 593 597.
21. Pocock, S.J. (1983) Clinical Trials: A Practical Approach. John Wiley, Chichester, NY.
22. Naqvi, T.Z., Shah, P.K., Ivey, P.A., Molloy, M.D., Thomas, A.M., Panicker, S., Ahmed, A., Cercek, B. Kaul, S. (1999) Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. American Journal of Cardiology, 84, 1011 1017.
23. Nofer, J.R., Kehrel, B., Fobker, M., Levkau, B., Assmann, G. von Eckhardstein, A. (2002) HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis, 161, 1 16.
24. Zilversmit, D.B. (1979) Atherogenesis: a postprandial phenomenon. Circulation, 60, 473 485.
25. Le Goff, W., Guerin, M. Chapman, M.J. (2004) Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Pharmacological Therapeutics, 101, 17 38.
26. Arai, T., Yamashita, S., Hirano, K., Sakai, N., Kotani, K., Fujioka, S., Nozaki, S., Keno, Y., Yamane, M. Shinohara, E. (1994) Increased plasma cholesteryl ester transfer protein in obese subjects. A possible mechanism for the reduction of serum HDL cholesterol levels in obesity. Arteriosclerosis and Thrombosis, 14, 1129 1136.
27. Martin, L.J., Connelly, P.W., Nancoo, D., Wood N., Zhang, Z.J., Maguire, G., Quinet, E., Tall, A.R., Marcel, Y.L. McPherson, R. (1993) Cholesteryl ester transfer protein and high density lipoprotein responses to cholesterol feeding in men: relationship to apolipoprotein E genotype. Journal of Lipid Research, 34, 437 446.
28. Guerin, M., Le Goff, W., Lassel, T.S., Van Tol, A., Steiner, G. Chapman, M.J. (2001) Atherogenic role of elevated CE transfer from HDL to VLDL (1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 21, 282 288.
29. van Venrooij, F.V., Stolk, R.P., Banga, J.D., Sijmonsma, T.P., van Tol, A., Erkelens, D.W. Dallinga-Thie, G.M. for the DALI Study Group (2003) Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care, 26, 1216 1223.